Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

Article  PubMed  Google Scholar 

Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023;73(5):480–515.

Article  PubMed  Google Scholar 

Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical adjuvant breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–85.

Article  PubMed  Google Scholar 

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.

Article  Google Scholar 

Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, et al. Neoadjuvant endocrine therapy for Estrogen receptor-positive breast Cancer: a systematic review and Meta-analysis. JAMA Oncol. 2016;2(11):1477–86.

Article  PubMed  PubMed Central  Google Scholar 

Morrison L, Loibl S, Turner NC. The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2024;21(2):89–105.

Article  CAS  PubMed  Google Scholar 

Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, et al. Potent cell-cycle inhibition and upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR(+)/HER2(-) breast Cancer. Clin Cancer Res. 2020;26(3):566–80.

Article  CAS  PubMed  Google Scholar 

Khan QJ, O’Dea A, Bardia A, Kalinsky K, Wisinski KB, O’Regan R, et al. Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER + breast cancer (FELINE trial). J Clin Oncol. 2020;38(15_suppl):505.

Article  Google Scholar 

Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, et al. Randomized phase II study evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen receptor-positive early breast Cancer: PALLET trial. J Clin Oncol. 2019;37(3):178–89.

Article  CAS  PubMed  Google Scholar 

Wang J, Li Q, Yuan J, Wang J, Chen Z, Liu Z, et al. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated rb and inducing G1 cell cycle arrest. J Transl Med. 2017;15(1):127.

Article  PubMed  PubMed Central  Google Scholar 

Long F, He Y, Fu H, Li Y, Bao X, Wang Q, et al. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. Cancer Sci. 2019;110(4):1420–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24(6):646–57.

Article  CAS  PubMed  Google Scholar 

Zhang L, Yang C, Ma J, Li Y, Luo R, Han J, et al. Abstract PO2-02-05: CDK4/6 inhibitor dalpiciclib combined with letrozole as neoadjuvant therapy in postmenopausal patients with hormone receptor-positive, HER2-negative stage II-III breast cancer: a single-arm exploratory trial. Cancer Res. 2024;84(9_Supplement):PO2–02.

Google Scholar 

Chen R, Yu Y, Zhang J, Song C, Wang C. Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a bayesian network meta-analysis. Expert Rev Anticancer Ther. 2024;24(7):599–611.

Article  CAS  PubMed  Google Scholar 

Martinez-Perez C, Turnbull AK, Kay C, Dixon JM. Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer. Expert Rev Anticancer Ther. 2023;23(1):67–86.

Article  CAS  PubMed  Google Scholar 

Cao L, Sugumar K, Keller E, Li P, Rock L, Simpson A, et al. Neoadjuvant endocrine therapy as an alternative to Neoadjuvant Chemotherapy among hormone receptor-positive breast Cancer patients: Pathologic and Surgical outcomes. Ann Surg Oncol. 2021;28(10):5730–41.

Article  PubMed  PubMed Central  Google Scholar 

Cottu P, D’Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018;29(12):2334–40.

Article  CAS  PubMed  Google Scholar 

Prat A, Saura C, Pascual T, Hernando C, Munoz M, Pare L, et al. Ribociclib plus Letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33–43.

Article  CAS  PubMed  Google Scholar 

Zhou Y, Zhang Z, Chen H, Miao Y, Chen Y. Neoadjuvant dalpiciclib combined with aromatase inhibitors in stage I-III HER2 negative luminal B breast cancer (DANCER): preliminary findings from an ongoing phase II study. J Clin Oncol. 2024;42(16_suppl):e12622–e.

Article  Google Scholar 

Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381.

Article  PubMed  PubMed Central  Google Scholar 

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, et al. NeoPalAna: Neoadjuvant Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and Anastrozole for Clinical Stage 2 or 3 estrogen receptor-positive breast Cancer. Clin Cancer Res. 2017;23(15):4055–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alsaleh K, Al Zahwahry H, Bounedjar A, Oukkal M, Saadeddine A, Mahfouf H, et al. Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial. J Cancer Res Clin Oncol. 2023;149(9):6171–9.

Article  CAS  PubMed  Google Scholar 

Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, et al. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023;24(9):1029–41.

Article  CAS  PubMed  Google Scholar 

Majidzadeh -AK, Esmaeili R, Abdoli N. TFRC and ACTB as the best reference genes to quantify urokinase plasminogen activator in breast cancer. BMC Res Notes. 2011;4(1):215.

Article  Google Scholar 

Zhuang Y, Li X, Zhan P, Pi G, Wen G. MMP11 promotes the proliferation and progression of breast cancer through stabilizing Smad2 protein. Oncol Rep. 2021;45(4).

Cheng C-J, Lin Y-C, Tsai M-T, Chen C-S, Hsieh M-C, Chen C-L, et al. SCUBE2 suppresses breast Tumor Cell Proliferation and confers a favorable prognosis in invasive breast Cancer. Cancer Res. 2009;69(8):3634–41.

Article  CAS  PubMed  Google Scholar 

Wu Q, Tian P, He D, Jia Z, He Y, Luo W, et al. SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches. Cell Res. 2023;33(6):464–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced breast Cancer. N Engl J Med. 2016;375(20):1925–36.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as First-Line therapy for HR-Positive, advanced breast Cancer. N Engl J Med. 2016;375(18):1738–48.

Article  CAS  PubMed  Google Scholar 

Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021;27(11):1904–9.

Article  CAS  PubMed  Google Scholar 

Wekking D, Lambertini M, Dessi M, Denaro N, Bardanzellu F, Garrone O, et al. CDK4/6 inhibitors in the treatment of metastatic breast cancer: focus on toxicity and safety. Semin Oncol. 2023;50(6):131–9.

Article  CAS  PubMed